ALA 5000
Alternative Names: ALA-5000Latest Information Update: 24 Sep 2024
At a glance
- Originator Alar Pharmaceuticals
- Class Antipsychotics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Schizophrenia
Most Recent Events
- 10 Sep 2024 Preclinical trials in Schizophrenia in USA (SC) before September 2024 (Alar Pharmaceuticals pipeline, September 2024)